Does Neuromuscular Electrical Stimulation Benefit the Functional Ability of Elderly Patients With Chronic Obstructive Lung Disease (NEMS for COPD)

April 29, 2024 updated by: Ahmed Samir Abdelkhalik Youssef, Beni-Suef University

Background: Patients with COPD often experience skeletal muscle dysfunction. For those who are unable or unwilling to undertake physical training, neuromuscular electrical stimulation (NMES) may provide an alternative method of exercise training.

Objective: To investigate the effects of adding neuromuscular electrical stimulation of gluteus maximus, quadriceps and calf muscles to chest physiotherapy, compared to chest physiotherapy alone, on muscles strength (gluteus max., quadriceps, calf muscles), femoral blood flow physical and pulmonary function in severe COPD Patients.

Study Overview

Detailed Description

Material and methods: This study include a group of 60 patients (30 males and 30 females) diagnosed with severe COPD), their age is ranged 65-75 years, they will be randomly divided into two groups; study group (A) 30 patients and study group (B) 30 patients. Study group (A): The patients in this group will receive the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks. Study group (B): The patients in this group will receive the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, calf muscles, performed for 30 min /day for five days a week for three consecutive weeks. Femoral blood Flow, gluteus maximus, quadriceps and calf muscles strength and pulmonary function (FEV1/FVC) will be measured for both groups pre and post treatment.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Qinā, Egypt
        • Department of P.T for internal medicine, Faculty of Physical Therapy, South valley university, Qena, Egypt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • A diagnosis of COPD with FEV1/FVC <50% predicted as per the GOLD guidelines.
  • Self-reported dyspnea and/or arm fatigue during at least one activity of daily living that required arm exercise.
  • Dyspnea and/or physical activity fatigue were self-reported by the Borg Scale.
  • Before entering in the study, all patients had their pulmonary function optimized with long-acting bronchodilators and corticosteroids.

Exclusion Criteria:

  • • Patients with unstable angina pectoris.

    • Progressive ventricular dysrhythmia.
    • Intermittent claudication.
    • Implanted cardiac pacemakers.
    • Uncontrolled diabetes mellitus.
    • Peripheral vascular disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Group
The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks.
The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
Other Names:
  • Chest physical therapy
Experimental: Study Group
The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation (NMES) of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
Other Names:
  • Chest physical therapy plus NMES

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle strength measurement
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up
To determine the maximal muscle strength the Lafayette manual muscle test system (USER MANUAL) (MMT) Model 01163, White Plains, New York (10602) of gluteus maximus, quadriceps and calf muscles will be measured on right lower limb.
change from baseline to 3 weeks after intervention and 3 days as a follow-up
Pulmonary function test
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up
Pulmonary capacity and respiratory muscle functions will be assessed using the CPFS/D USB™ 187 Spirometer (Medical Graphics-MGC, St. Paul, MN, USA) with airflow being measured by a 188 calibrated Pitot tube (PreVent, Pneumotach). The participant completed at least three acceptable maximal forced and slow expiratory maneuvers after 15 min the inhalation of 400 mg of salbutamol 190 via a metered-dose inhaler. Forced vital capacity (FVC, L), forced expiratory volume in one second (FEV1, L), FEV1/ FVC, and inspiratory capacity (IC) will be measured according to American Thoracic Society standards
change from baseline to 3 weeks after intervention and 3 days as a follow-up
Six-minute walking test (Physical function assessment
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up

The six-minute walking distance (6MWD) was measured according to a standardized protocol.

  • Subjects were instructed to walk at their own pace along a 34.5-m corridor from one end to the other, covering as much ground as possible in the allotted time.
  • Subjects were allowed to stop and rest during the test, but they were instructed to resume walking as soon as they felt able to do
change from baseline to 3 weeks after intervention and 3 days as a follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood flow velocimetry measurement
Time Frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up
To evaluate changes in peripheral perfusion. The standard pulsed-wave Doppler velocimetry of the right femoral artery was performed using sonos 2000 echograph (Philips Envisor )
change from baseline to 3 weeks after intervention and 3 days as a follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Ibrahim I. I Abu zaid, PhD, Department of P.T for internal medicine, Faculty of Physical Therapy, South valley university, Qena, Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 2, 2023

Primary Completion (Actual)

August 13, 2023

Study Completion (Actual)

August 13, 2023

Study Registration Dates

First Submitted

April 2, 2023

First Submitted That Met QC Criteria

May 1, 2023

First Posted (Actual)

May 3, 2023

Study Record Updates

Last Update Posted (Actual)

April 30, 2024

Last Update Submitted That Met QC Criteria

April 29, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe